Relay Therapeutics Inc (RLAY)
$6.155
Insights on Relay Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 25.20M → -1.0K (in $), with an average decrease of 100.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -65.73M → -83.49M (in $), with an average decrease of 27.0% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.9% return, outperforming this stock by 97.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.5% return, outperforming this stock by 322.3%
Performance
- $5.82$6.20$6.16
5.52%
Downside
Day's Volatility :6.13%
Upside
0.65%
- $5.70$13.32$6.16
7.47%
Downside
52 Weeks Volatility :57.21%
Upside
53.75%
Returns
| Period | Relay Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -34.67% | 1.1% | 0.0% |
6 Months | 0.32% | 12.5% | 0.0% |
1 Year | -44.25% | 6.9% | 2.2% |
3 Years | -81.81% | 14.3% | -23.0% |
Highlights
Market Capitalization | 774.0M |
Book Value | $5.9 |
Earnings Per Share (EPS) | -2.79 |
Wall Street Target Price | 23.05 |
Profit Margin | 0.0% |
Operating Margin TTM | 9426300.0% |
Return On Assets TTM | -24.4% |
Return On Equity TTM | -40.18% |
Revenue TTM | 25.5M |
Revenue Per Share TTM | 0.21 |
Quarterly Revenue Growth YOY | 7226.2% |
Gross Profit TTM | 1.4M |
EBITDA | -374.2M |
Diluted Eps TTM | -2.79 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.94 |
EPS Estimate Next Year | -2.88 |
EPS Estimate Current Quarter | -0.73 |
EPS Estimate Next Quarter | -0.79 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 274.49%
Technicals Summary
Sell
Neutral
Buy
Relay Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Relay Therapeutics Inc | -16.12% | 0.32% | -44.25% | -81.81% | -81.88% |
 Moderna, Inc. | 1.34% | 41.81% | -16.73% | -38.71% | 314.51% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -4.23% | 10.39% | 23.96% | 84.71% | 131.85% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Relay Therapeutics Inc | NA | NA | NA | -2.94 | -0.4 | -0.24 | NA | 5.9 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Relay Therapeutics Inc | Buy | $774.0M | -81.88% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 314.51% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 131.85% | 29.17 | 36.68% |
Institutional Holdings
SB INVESTMENT ADVISERS (UK) LTD
21.27%Vanguard Group Inc
8.12%BlackRock Inc
7.30%T. Rowe Price Associates, Inc.
6.54%Casdin Capital, LLC
5.63%JPMorgan Chase & Co
4.62%
Corporate Announcements
Relay Therapeutics Inc Earnings
Relay Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate
Organization | Relay Therapeutics Inc |
Employees | 323 |
CEO | Mr. Alexis A. Borisy A.M. |
Industry | Health Technology |
